Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan in Advanced Small Bowel Adenocarcinoma
NCT07720258Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2027
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in small bowel adenocarcinoma (SBA), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on NCT07720258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07720258.